Zeitschrift fur Rheumatologie最新文献_第10页

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-11-01 DOI: 10.1007/s00393-024-01586-9

引用次数: 0

[Current patient care of systematic lupus erythematosus in Rhineland-Palatinate and Saarland]. [莱茵兰-法尔茨州和萨尔州系统性红斑狼疮患者护理现状]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-11-01 Epub Date: 2024-03-20 DOI: 10.1007/s00393-024-01491-1

Ciaran Alberti, Matthias Dreher, Konstantinos Triantafyllias, Andreas Schwarting

{"title":"[Current patient care of systematic lupus erythematosus in Rhineland-Palatinate and Saarland].","authors":"Ciaran Alberti, Matthias Dreher, Konstantinos Triantafyllias, Andreas Schwarting","doi":"10.1007/s00393-024-01491-1","DOIUrl":"10.1007/s00393-024-01491-1","url":null,"abstract":"Background: Systemic lupus erythematosus (SLE) is a clinically heterogeneous autoimmune disease that is associated with great suffering for those affected, as well as high socioeconomic costs. Early diagnosis and adequate medical care are essential for a mild course of the disease. However, there is a lack of current figures and data on the care situation of patients in the area.Methodology: A total of 1546 general practitioners, rheumatologists, neurologists, nephrologists and dermatologists in Rhineland-Palatinate and Saarland were interviewed by fax or mail using a questionnaire regarding epidemiology, symptoms, therapy and therapy success. In addition, there was the possibility of making suggestions for improvement.Results: Five out of six of the 635 reported SLE patients were female. The most common main symptoms were arthralgia, fatigue, myalgia, and skin changes. Of the patients, 68% received antimalarials (AMs), whereas 46% were treated with glucocorticoids (GCs) and 50% with an immunosuppressant (IS), mainly methotrexate. In terms of comorbidities, patients suffered mainly from cardiovascular disease, fibromyalgia syndrome and depression. Rheumatologists also frequently described anaemia, diabetes mellitus and osteoporosis.Discussion: Compared with guideline recommendations, the low rate of AMs in therapy was particularly striking in patients not treated by rheumatologists (35% on average compared with 81% for rheumatologists). Additionally, (sustained) high doses of GCs are not in line with literature recommendations. In the free text field, the main requests were for more rheumatologists in private practice and faster appointment scheduling, as well as better communication and networking. In addition, the desire for more training and education was frequently expressed..","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"770-777"},"PeriodicalIF":0.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140176738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Head-to-head studies on psoriasis and psoriatic arthritis]. [关于银屑病和银屑病关节炎的头对头研究]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-10-01 Epub Date: 2024-08-14 DOI: 10.1007/s00393-024-01556-1

Fredrik N Albach, Michaela Köhm, David Simon

{"title":"[Head-to-head studies on psoriasis and psoriatic arthritis].","authors":"Fredrik N Albach, Michaela Köhm, David Simon","doi":"10.1007/s00393-024-01556-1","DOIUrl":"10.1007/s00393-024-01556-1","url":null,"abstract":"Given the ever-increasing number of approved therapies for the treatment of psoriasis (PsO) and psoriatic arthritis (PsA), head-to-head (H2H) comparative studies are essential. These are aimed primarily at a comparative analysis of treatment effectiveness. In both PsO and PsA, biological disease-modifying antirheumatic drugs (bDMARD) have been shown to be superior to conventional therapies in H2H studies. In PsO interleukin 17 (IL-17) and IL-23 inhibitors proved superiority compared to tumor necrosis factor (TNF) inhibitors (etanercept and adalimumab) in several studies. Ustekinumab was more effective than etanercept, but less effective than IL-17 and IL-23 inhibitors. Only a few H2H studies have been published on the treatment of PsA. In the Spirit H2H study ixekizumab was superior to adalimumab using a combined endpoint of arthritis and psoriasis response (ACR-50 and PASI-100). When looking at arthritic symptoms only (ACR-20), secukinumab was not significantly superior to adalimumab in the EXCEED study but was superior in terms of the effect on skin involvement (PASI90). Other H2H studies focused on the treatment of enthesitis (ECLIPSA study), the efficacy of Janus kinase (JAK) inhibition (SELECT-PSA-1) or the additional administration of methotrexate to bDMARD treatment (MUST study). The H2H data have been incorporated into the treatment guidelines and have led to IL-17 and IL-23 inhibition being preferred over TNF inhibition in cases of relevant skin involvement in PsA.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"634-640"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Head-to-head trials in rheumatoid arthritis]. [类风湿性关节炎的头对头试验]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-10-01 Epub Date: 2024-06-03 DOI: 10.1007/s00393-024-01517-8

Diana Ernst, Klaus Krüger, Torsten Witte

引用次数: 0

[Head-to-head studies in rheumatology]. [风湿病学头对头研究]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-10-01 Epub Date: 2024-10-16 DOI: 10.1007/s00393-024-01578-9

Gerd R Burmester, Frank Behrens

引用次数: 0

[Swelling of the salivary glands and sicca symptoms in Kimura's disease, a rare rheumatological differential diagnosis with an indicatively high IgE serum level-A current overview after literature search]. [木村氏病的唾液腺肿胀和眼科症状--一种罕见的风湿病鉴别诊断，血清 IgE 水平较高--文献检索后的综述]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-10-01 Epub Date: 2023-09-14 DOI: 10.1007/s00393-023-01411-9

Jürgen Braun, Kirsten Karberg

引用次数: 0

[Head-to-head studies on connective tissue diseases and vasculitides]. [结缔组织疾病和血管病的正面研究]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-10-01 Epub Date: 2024-07-17 DOI: 10.1007/s00393-024-01537-4

Bernhard Hellmich, Johanna Mucke, Martin Aringer

{"title":"[Head-to-head studies on connective tissue diseases and vasculitides].","authors":"Bernhard Hellmich, Johanna Mucke, Martin Aringer","doi":"10.1007/s00393-024-01537-4","DOIUrl":"10.1007/s00393-024-01537-4","url":null,"abstract":"Head-to-head (H2H) studies enable the direct comparison of several alternative therapeutic approaches and thus provide the evidence-based foundation for the relative position of one treatment as compared to others for a specific indication. These trials constitute an important addition to placebo-controlled clinical trials. Among the controlled clinical trials not performed by the pharmaceutical industry, there are a relevant number of H2H trials for connective tissue diseases (CTDs) and vasculitides, particularly for systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This article encompasses a review of the H2H trials for CTDs and vasculitides and discusses their relevance for current treatment algorithms. For SLE the H2H trials were predominantly performed for the treatment of lupus nephritis, demonstrating the impact of low-dose cyclophosphamide and mycophenolate as well as azathioprine for maintenance therapy. In recent H2H trials rituximab could be established as induction and maintenance therapy for AAV, which has now been incorporated into current treatment guidelines. Further comparative trials will be necessary in order to select the most effective and safest treatment for every patient, in the sense of personalized medicine.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"620-628"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141627823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Is lymphoma screening necessary in Sjögren`s disease, and if so, how?] [是否有必要对斯约格伦病患者进行淋巴瘤筛查，如果有必要，如何筛查？］

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-10-01 Epub Date: 2024-09-12 DOI: 10.1007/s00393-024-01562-3

Torsten Witte

引用次数: 0

[Head-to-head studies on radiographic progression in axial spondyloarthritis]. [轴性脊柱关节炎放射学进展的头对头研究]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-10-01 Epub Date: 2024-05-21 DOI: 10.1007/s00393-024-01518-7

Uta Kiltz, Hildrun Haibel

{"title":"[Head-to-head studies on radiographic progression in axial spondyloarthritis].","authors":"Uta Kiltz, Hildrun Haibel","doi":"10.1007/s00393-024-01518-7","DOIUrl":"10.1007/s00393-024-01518-7","url":null,"abstract":"In this review article four clinical comparative studies in axial spondylarthritis (axSpA) are presented and discussed. SURPASS as the only head-to-head study investigated the effect of adalimumab biosimilar disease-modifying antirheumatic drug (bsDMARD) or secukinumab on radiographic progression over a time period of 2 years. Overall, the radiographic progression of the spine was low and no significant difference between adalimumab bsDMARD or secukinumab was noted. The three other studies were not constructed as direct head-to-head studies but compared the efficacy of non-steroidal antirheumatic drugs (NSARD) with and without simultaneous treatment with biological DMARDs (bDMARD). The CONSUL study showed no statistically significant difference in the delay of radiographic progression of the spine over 2 years in radiographic axSpA (r-axSpA) patients, who underwent either combined treatment with golimumab and celecoxib or treatment with golimumab alone over 2 years. The ESTHER study showed that patients with early axSpA active inflammatory lesions, which were detected by whole-body magnetic resonance imaging (MRI), showed a significantly greater improvement under treatment with etanercept than those treated with sulfasalazine. The INFAST study showed that patients with early active axSpA who received a combined treatment of infliximab and naproxen, achieved a clinical remission twice as frequently as those who only received naproxen. Therefore, for the endpoint of radiological progression no difference could be shown in the inhibition of radiological progression between the mechanisms of action investigated. The comparative data for the endpoint of clinical efficacy showed that patients with bDMARDs showed a clearly better response to treatment than patients with NSAR or conventional synthetic DMARDs (csDMARD).","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"629-633"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141072045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[The subanalysis of Rheuma-VOR demonstrates a considerable need for rheumatological care]. [Rheuma-VOR 的子分析表明，对风湿病护理的需求相当大]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-10-01 Epub Date: 2024-03-08 DOI: 10.1007/s00393-024-01490-2

Stefanie Hirsch, K Hoeper, D Meyer-Olson, A Schwarting, K Gente, M Dreher, J Hoeper, T Witte, T Thiele

{"title":"[The subanalysis of Rheuma-VOR demonstrates a considerable need for rheumatological care].","authors":"Stefanie Hirsch, K Hoeper, D Meyer-Olson, A Schwarting, K Gente, M Dreher, J Hoeper, T Witte, T Thiele","doi":"10.1007/s00393-024-01490-2","DOIUrl":"10.1007/s00393-024-01490-2","url":null,"abstract":"Background: Early diagnosis and treatment of inflammatory rheumatic diseases can prevent consequential damage such as permanently limited mobility and joint or organ damage. Simultaneously, there is an increasing deficit in medical care owing to the lack of rheumatological capacity. Rural regions are particularly affected.Objectives: The available unconfirmed diagnoses of the study Rheuma-VOR were analysed regarding another definitive inflammatory rheumatic disease.Materials and methods: The returned questionnaires of the rheumatologists participating in Rheuma-VOR were screened for definitive inflammatory rheumatic diseases other than the required diagnosis of rheumatoid arthritis, psoriatic arthritis or spondyloarthritis.Results: Of 910 unconfirmed diagnoses, in 245 patients another definitive diagnosis could be confirmed. A total of 29.8% of the diagnoses corresponded to degenerative joint changes or chronic pain syndrome, whereas 26.1% involved different forms of inflammatory arthritis. The majority of diagnoses (40.5%) were collagenosis or vasculitis, DISCUSSION: The available data show that a rheumatological presentation was indicated for the majority of patients. Owing to the increasing deficits in medical care a prior selection of the patients is crucial to make optimal use of restricted rheumatological capacities.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"679-685"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140060609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0